Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs
